Glenmark Pharmaceuticals receives USFDA final approval for Abiraterone Acetate Tablets

Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Abiraterone Acetate Tablets USP, 250 mg, a generic version of Zytiga1 Tablets, 250 mg, of Janssen Biotech, Inc.

According to IQVIATM sales data for the 12 month period ending August 2019, the Zytiga Tablets, 250 mg market achieved annual sales of approximately $794.1 million.

Powered by Capital Market - Live News